[
  {
    "ts": "2026-02-19T01:15:49+00:00",
    "headline": "Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation",
    "summary": "Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity. The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics. The LIBRETTO-432 Phase 3 trial of Retevmo in early-stage RET fusion positive lung cancer met its primary goal in the adjuvant setting. Eli Lilly, trading at $1,020.56, has seen a very large 3-year return and a 424.5%...",
    "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5afe4d13-0e39-3acb-8ce2-f12c29e9edad",
      "content": {
        "id": "5afe4d13-0e39-3acb-8ce2-f12c29e9edad",
        "contentType": "STORY",
        "title": "Eli Lilly Trial Wins And Gene Editing Progress Versus Current Valuation",
        "description": "",
        "summary": "Eli Lilly (NYSE:LLY) reported successful results from the TOGETHER-PsO Phase 3b trial combining Taltz and Zepbound for patients with psoriasis and obesity. The company reached a second key milestone in its CRISPR-based gene editing collaboration with Scribe Therapeutics. The LIBRETTO-432 Phase 3 trial of Retevmo in early-stage RET fusion positive lung cancer met its primary goal in the adjuvant setting. Eli Lilly, trading at $1,020.56, has seen a very large 3-year return and a 424.5%...",
        "pubDate": "2026-02-19T01:15:49Z",
        "displayTime": "2026-02-19T01:15:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-trial-wins-gene-011549892.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T11:08:24+00:00",
    "headline": "Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders",
    "summary": "By Michael Erman NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky",
    "url": "https://finance.yahoo.com/news/analysis-hims-hers-glp-1-110420310.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "47b8c1eb-0334-3de3-b42a-4ca0bcf40134",
      "content": {
        "id": "47b8c1eb-0334-3de3-b42a-4ca0bcf40134",
        "contentType": "STORY",
        "title": "Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders",
        "description": "",
        "summary": "By Michael Erman NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky",
        "pubDate": "2026-02-19T11:08:24Z",
        "displayTime": "2026-02-19T11:08:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/c3bd5914142159b76d0ae6cd28583c25",
          "originalWidth": 800,
          "originalHeight": 450,
          "caption": "A man uses a mask while biking in this screenshot taken from an advertisement  that aired during the Super Bowl, in Vancouver, Canada, December 11, 2025.  Hims and Hers Health Inc./Handout via REUTERS",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hAU1.d0f5l_11HFuZqZnpg--~B/aD00NTA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/c3bd5914142159b76d0ae6cd28583c25.cf.webp",
              "width": 800,
              "height": 450,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UVd9YfRp.Eb9Wj5SuXO7Yg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/c3bd5914142159b76d0ae6cd28583c25.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-hims-hers-glp-1-110420310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-hims-hers-glp-1-110420310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-19T04:33:15+00:00",
    "headline": "2 High-Flying Stocks on Our Buy List and 1 Facing Challenges",
    "summary": "Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.",
    "url": "https://finance.yahoo.com/news/2-high-flying-stocks-buy-043315328.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "6dd84b28-07ce-3ff4-a8d3-6e8ae08e1f80",
      "content": {
        "id": "6dd84b28-07ce-3ff4-a8d3-6e8ae08e1f80",
        "contentType": "STORY",
        "title": "2 High-Flying Stocks on Our Buy List and 1 Facing Challenges",
        "description": "",
        "summary": "Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.",
        "pubDate": "2026-02-19T04:33:15Z",
        "displayTime": "2026-02-19T04:33:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/47ca92056da206f7d44e32b861940738",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "SWBI Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/scXecdFBk2ztUEjc6WZgZQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/47ca92056da206f7d44e32b861940738.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_ws9HQ1n1f6GuvfHToR_oA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/47ca92056da206f7d44e32b861940738.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-high-flying-stocks-buy-043315328.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-high-flying-stocks-buy-043315328.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "STRL"
            },
            {
              "symbol": "SWBI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]